- Home
- CHN vs RPID Comparison
CHN vs RPID Comparison
Compare CHN & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- RPID
- Stock Information
- Founded
- CHN 1992
- RPID 2006
- Country
- CHN United States
- RPID United States
- Employees
- CHN N/A
- RPID N/A
- Industry
- CHN Investment Managers
- RPID Medical Specialities
- Sector
- CHN Finance
- RPID Health Care
- Exchange
- CHN Nasdaq
- RPID Nasdaq
- Market Cap
- CHN 153.9M
- RPID 138.9M
- IPO Year
- CHN N/A
- RPID 2021
- Fundamental
- Price
- CHN $16.90
- RPID $2.47
- Analyst Decision
- CHN
- RPID Strong Buy
- Analyst Count
- CHN 0
- RPID 2
- Target Price
- CHN N/A
- RPID $8.00
- AVG Volume (30 Days)
- CHN 31.8K
- RPID 91.1K
- Earning Date
- CHN 01-01-0001
- RPID 08-12-2025
- Dividend Yield
- CHN 0.19%
- RPID N/A
- EPS Growth
- CHN N/A
- RPID N/A
- EPS
- CHN N/A
- RPID N/A
- Revenue
- CHN N/A
- RPID $30,289,000.00
- Revenue This Year
- CHN N/A
- RPID $16.63
- Revenue Next Year
- CHN N/A
- RPID $21.98
- P/E Ratio
- CHN N/A
- RPID N/A
- Revenue Growth
- CHN N/A
- RPID 22.57
- 52 Week Low
- CHN $9.00
- RPID $0.80
- 52 Week High
- CHN $12.98
- RPID $4.50
- Technical
- Relative Strength Index (RSI)
- CHN 66.99
- RPID 36.66
- Support Level
- CHN $16.71
- RPID $2.40
- Resistance Level
- CHN $17.32
- RPID $2.92
- Average True Range (ATR)
- CHN 0.26
- RPID 0.25
- MACD
- CHN 0.01
- RPID -0.02
- Stochastic Oscillator
- CHN 73.58
- RPID 13.26
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.